Status: Not yet recruiting
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors
Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Brigham and Women's HospitalUpdated: May 18, 2026Locations: 1
Eligibility criteria
Adults (≥ 18 years old) with active malignancy who are currently treated with VS... [+2]
Estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 [+20]